<SEC-DOCUMENT>0001193125-24-273969.txt : 20241210
<SEC-HEADER>0001193125-24-273969.hdr.sgml : 20241210
<ACCEPTANCE-DATETIME>20241210073811
ACCESSION NUMBER:		0001193125-24-273969
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20241210
DATE AS OF CHANGE:		20241210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Korro Bio, Inc.
		CENTRAL INDEX KEY:			0001703647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				472324450
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275353
		FILM NUMBER:		241537141

	BUSINESS ADDRESS:	
		STREET 1:		60 FIRST STREET
		STREET 2:		2ND FLOOR, SUITE 250
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		617-468-1999

	MAIL ADDRESS:	
		STREET 1:		60 FIRST STREET
		STREET 2:		2ND FLOOR, SUITE 250
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Frequency Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170412
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d870524d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(3)<BR> Registration Statement No. 333-275353 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g870524g04x04.jpg" ALT="LOGO" STYLE="width:1.51667in;height:0.2875in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 1,504,537 Shares of Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the proposed offer and resale or other disposition from time to time by the selling stockholders identified in this
prospectus of up to an aggregate of 1,504,537 shares of common stock, par value $0.001 per share, of Korro Bio, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering
the resale of the shares of common stock pursuant to the selling stockholders&#146; registration rights under a registration rights agreement between us and the selling stockholders. Our registration of the resale of the shares of common stock
covered by this prospectus does not mean that the selling stockholders will offer or sell all or any of the shares of common stock. The selling stockholders may offer, sell or distribute all or a portion of their shares of common stock from time to
time directly or indirectly through one or more underwriters, broker-dealers or agents, and in one or more public or private transactions. The shares of common stock may be sold in one or more transactions at fixed prices, at prevailing market
prices at the time of the sale, at varying prices determined at the time of sale or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. See the section entitled &#147;<I>Plan of
Distribution</I>&#148; for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds from any sale of common stock by the selling stockholders
pursuant to this prospectus. We have agreed to bear the expenses in connection with the registration of the resale of the shares of common stock to be offered by this prospectus by the selling stockholders other than any underwriting discounts and
commissions or transfer taxes relating to the sale of common stock, which will be borne by the selling stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company&#148; as defined under the federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and our other filings with the Securities and
Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market, or Nasdaq, under the symbol &#147;KRRO.&#148; On
December&nbsp;6, 2024, the closing price for our common stock, as reported on Nasdaq, was $42.58 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>See the
section entitled &#147;<A HREF="#rom870524_4">Risk Factors</A>&#148; beginning on page&nbsp;4 of this prospectus to read about factors you should consider before buying our securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this
prospectus is December&nbsp;9, 2024. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom870524_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom870524_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">iii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom870524_3">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom870524_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom870524_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom870524_6">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom870524_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom870524_8">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom870524_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom870524_10">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom870524_11">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information provided in this prospectus, as well as the information incorporated by reference herein and to exhibits to the
registration statement of which this prospectus forms a part and any applicable prospectus supplement or amendment. Neither we nor the selling stockholders have authorized anyone to provide you with different information. Neither we nor the selling
stockholders are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than
the date of the applicable document. Since the date of this prospectus and the documents filed as exhibits to the registration statement of which this prospectus forms a part, our business, financial condition, results of operations and prospects
may have changed. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom870524_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the SEC utilizing a &#147;shelf&#148; registration process. Under this
shelf registration process, the selling stockholders may, from time to time, sell the shares of common stock described in this prospectus in one or more offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we, nor the selling stockholders, have authorized anyone to give any information or to make any representation other than those
contained or incorporated by reference in this prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus. The selling stockholders are offering to sell, and seeking offers to
buy, shares of our common stock only in jurisdictions where it is lawful to do so. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any shares other than the registered shares to which it relates, nor does
this prospectus constitute an offer to sell or the solicitation of an offer to buy shares in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information
contained in this prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated
by reference, even though this prospectus is delivered or shares are sold on a later date. Our business, financial condition, results of operations and prospects may have changed since those dates. This prospectus incorporates by reference market
data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this
information and we have not independently verified this information. In addition, the market and industry data and forecasts that may be included or incorporated by reference in this prospectus may involve estimates, assumptions and other risks and
uncertainties and are subject to change based on various factors, including those discussed under the heading &#147;Risk Factors&#148; contained in this prospectus, and under similar headings in other documents that are incorporated by reference
into this prospectus. Accordingly, investors should not place undue reliance on this information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement may add to,
update or change the information contained in this prospectus. You should read both this prospectus and any applicable prospectus supplement together with additional information described below under the heading &#147;Where You Can Find Additional
Information&#148; or incorporated by reference herein as described under the heading &#147;Incorporation of Certain Information by Reference.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;3, 2023, we consummated the previously announced business combination, or the Merger, pursuant to that certain Agreement and
Plan of Merger, or the Merger Agreement, dated July&nbsp;14, 2023, by and among our company (formerly known as Frequency Therapeutics, Inc., or Frequency), Frequency Merger Sub, Inc., or Merger Sub, and Korro Bio Ops, Inc., or Legacy Korro. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Merger Agreement, a business combination between Frequency and Legacy Korro was effected through the merger of
Merger Sub with and into Legacy Korro, with Legacy Korro surviving as a wholly owned subsidiary of Frequency. On the Merger closing date, Frequency changed its name to Korro Bio, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise indicates, references in this prospectus to &#147;Company,&#148; &#147;we,&#148; &#147;our&#148; and
&#147;us&#148; refer, collectively, to Korro Bio, Inc., a Delaware corporation, and its consolidated subsidiaries (including Legacy Korro). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use various trademarks and trade names in our business, including without limitation our corporate name and logo. All other trademarks or
trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the
<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the
fullest extent under applicable law, their rights thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom870524_2"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents we have filed with the SEC that are incorporated by reference herein contain statements that are not
historical facts and are considered forward-looking within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange
Act. Our forward-looking statements include, but are not limited to, statements regarding our or our management team&#146;s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to
projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;contemplate,&#148;
&#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148;
&#147;should,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this
prospectus and the documents w have filed with the SEC that are incorporated by reference herein may include, for example, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress, results, and cost of our research and development programs and our current and
future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and
our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our cash runway and ability to reach data inflection points; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the therapeutic and commercial potential of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our research and development and other expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our
business and operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect our intellectual property and operate our business without infringing upon the
intellectual property rights of others, including our ability to obtain and maintain rights to the technologies required to develop and commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitive developments, including the impact on our competitive position of rival products and product
candidates and our ability to meet such competition; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to manage the growth of our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual
results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements, including those set forth in the
section titled &#147;Risk Factors&#148; and elsewhere in this prospectus and in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report
on Form <FONT STYLE="white-space:nowrap">8-K</FONT> as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety, together with other information in this
prospectus, the documents incorporated by reference and any free writing prospectus that we may authorize for use in connection with a specific offering. Given these risks and uncertainties, you should not place undue reliance on these
forward-looking statements. Should one or more of the risks or uncertainties occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as
otherwise required by applicable law, we disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this annual report. We
qualify all of our forward-looking statements by these cautionary statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These risks are not exhaustive. Other sections of this
prospectus may include additional factors that could harm our business and financial performance. Moreover, we operate in a very competitive and rapidly changing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
environment. New risks and uncertainties emerge from time to time, and it is not possible for our management to predict all risks and uncertainties, nor can we assess the impact of all such
factors on our business or the extent to which any such factor, or combination of such factors, may cause actual results to differ from those contained in, or implied by, any forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, any applicable prospectus supplement, together with the documents we have filed with the SEC that are
incorporated by reference herein and therein and any free writing prospectuses that we may authorize for use in connection with a specific offering completely and with the understanding that our actual future results, levels of activity, performance
and achievements may be different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom870524_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are generating a portfolio of differentiated programs that are designed to harness the body&#146;s natural RNA editing process to effect a
precise yet transient single base edit. By editing RNA instead of DNA, we are expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term
tolerability. Using an oligonucleotide-based approach, we expect to bring our medicines to patients by leveraging our proprietary platform with precedented delivery modalities, manufacturing <FONT STYLE="white-space:nowrap">know-how,</FONT> and
established regulatory pathways of approved oligonucleotide drugs. However, the scientific evidence to support the feasibility of developing product candidates using our RNA editing technology is both preliminary and limited. Moreover, regulators
have not yet established any definitive guidelines related to overall development considerations for RNA editing therapies and limited clinical data has been generated to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The versatility of RNA editing combined with our RNA editing platform, Oligonucleotide Promoted Editing of RNA, or OPERA, broadens the
therapeutic target space significantly. While our approach can be used to repair pathogenic single nucleotide variants, or SNVs, as demonstrated by our most advanced program, our <FONT STYLE="white-space:nowrap">Alpha-1</FONT> Antitrypsin
Deficiency, or AATD, product candidate, we can also engineer de novo SNVs and change amino acids on proteins to endow them with desired properties while preserving their broader functional capabilities, as exemplified by three of our other programs
(severe Alcoholic Hepatitis, or SAH, amyotrophic lateral sclerosis, or ALS, Pain). In preclinical studies, we have demonstrated that single RNA changes can disrupt protein-protein interactions, prevent protein aggregation, selectively modulate ion
channels and activate kinases. These modification approaches can unlock validated target classes that have historically been difficult to drug, enabling us to pursue a broad range of diseases traditionally <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-scope</FONT></FONT> for other genetic medicine approaches and current traditional drug modalities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
most advanced program is a development candidate, <FONT STYLE="white-space:nowrap">KRRO-110,</FONT> for the treatment of AATD where, using our proprietary RNA editing approach, we are repairing a pathogenic variant on RNA. <FONT
STYLE="white-space:nowrap">KRRO-110</FONT> has the potential to be disease-modifying and provide a differentiated therapeutic option. In November 2024, we received approval from the Australian Bellberry Human Research Ethics Committee, or HREC, and
Clinical Trial Notification clearance from the Australian Therapeutic Goods Administration, or TGA, to initiate a Phase&nbsp;1/2 clinical trial of <FONT STYLE="white-space:nowrap">KRRO-110</FONT> for AATD in Australia. An interim data readout for
the Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">KRRO-110</FONT> is anticipated in the second half of 2025, and completion of the clinical trial is expected in 2026.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, we have focused primarily on organizing and staffing our company, business planning, raising capital, securing related
intellectual property, and conducting research and development activities for our potential programs and product candidates. Since inception, we have funded our operations primarily through the private placement of our equity securities. We have
incurred significant operating losses since inception. We expect to continue to incur significant and increasing expenses and operating losses and negative operating cash flows for the foreseeable future as we continue our research and development
efforts, advance product candidates through clinical stages, and seek regulatory approvals for our pipeline candidates. We also expect to incur additional costs associated with maintaining compliance with Nasdaq listing rules and the requirements of
the SEC, director and officer liability insurance, investor and public relations activities and other expenses associated with operating as a public company. Our net losses may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our preclinical studies, initiation and conduct of any clinical
trials, and our expenditures on other research and development activities, including the expansion of our pipeline. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any product candidates approved for sale and have not generated any revenue
from product sales. We will not generate revenue from product sales unless and until we successfully obtain regulatory approval for our product candidates, if ever, and as appropriate, move pipeline candidates into the clinic and complete clinical
development. We have yet to commence clinical trials on any of our program candidates. If we obtain regulatory approval for our product candidates and do not enter into third-party commercialization partnerships, we expect to incur significant
expenses related to developing commercialization capabilities to support product sales, marketing, manufacturing and distribution activities. As a result, we will need substantial additional funding to support our continuing operations and pursue
our development and growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private offerings of securities, debt financings or other sources,
such as potential collaboration agreements, strategic alliances and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to
raise capital or enter into such agreements as, and when needed, could have a negative effect on our business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated under the laws of the state of Delaware in November 2014 under the name &#147;Frequency Therapeutics, Inc.&#148;, which was changed to &#147;Korro Bio, Inc.&#148; on the Merger closing date. Our principal executive offices are located
at 60 First Street, 2nd floor, Suite 250, Cambridge, Massachusetts 02141, and our telephone number is (617) <FONT STYLE="white-space:nowrap">468-1999.</FONT> Our website address is www.korrobio.com. We do not incorporate the information on or
accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus. Our common stock is listed on Nasdaq under the symbol &#147;KRRO.&#148;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may take
advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. We may take advantage of these exemptions until we are no longer an emerging growth company
under Section&nbsp;107 of the JOBS Act, which provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. We have elected to
avail ourselves of the extended transition period and, therefore, while we are an emerging growth company, we will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are
not emerging growth companies, unless we choose to early adopt a new or revised accounting standard. We will remain an emerging growth company until December&nbsp;31, 2024, which is the fifth anniversary of the closing of our initial public
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are a &#147;smaller reporting company&#148; as defined in Item 10(f)(1) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller
reporting company until the last day of the fiscal year in which (i)&nbsp;the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $250&nbsp;million as of the prior June&nbsp;30, or (ii)&nbsp;our
annual revenues exceed $100&nbsp;million during such completed fiscal year and the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the information in this prospectus and that we provide to our investors in the future may be different than what you might
receive from other public reporting companies. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Offering </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuer </P></TD>
<TD>Korro Bio, Inc. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock Offered by the Selling Stockholders </P></TD>
<TD>1,504,537 shares of common stock </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We will not receive any proceeds from the sale of the shares of common stock covered by this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Symbol </P></TD>
<TD>KRRO </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Offering Price </P></TD>
<TD>The selling stockholders will offer the shares of common stock offered by this prospectus at the prevailing market prices or at privately negotiated prices. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>You should read the &#147;<I>Risk Factors</I>&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information concerning the offering, see &#147;<I>Plan of Distribution</I>&#148; beginning on page&nbsp;8. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom870524_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described under &#147;Risk Factors&#148;
in our most recent Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and in our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as any accompanying prospectus supplement, together with
all of the other information included or incorporated by reference in this prospectus and in any accompanying prospectus supplement, including our consolidated financial statements and related notes, before deciding whether to purchase our
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business, financial condition and results of operations could be materially and adversely affected by any or all of these risks or by
additional risks and uncertainties not presently known to us or that we currently deem immaterial that may adversely affect us in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom870524_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the potential resale from time to time of some or all of 1,504,537 shares of our common stock. The selling
stockholders will receive all of the proceeds from any sale of such shares. We will not receive any proceeds from any sales of shares of our common stock by the selling stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to bear the expenses in connection with the registration of the shares of common stock to be offered by this prospectus by the
selling stockholders other than any underwriting discounts and commissions or transfer taxes relating to the sale of common stock, which will be borne by the selling stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom870524_6"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders acquired shares of common stock from us in the Merger upon exchange of shares of Legacy Korro acquired from Legacy
Korro immediately prior to the Merger pursuant to an exemption from registration under Section&nbsp;4(a)(2) of the Securities Act. Under the registration rights agreement that we assumed in the Merger, we agreed to file a registration statement with
the SEC for the purposes of registering for resale from time to time the shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below lists the selling
stockholders and other information regarding their ownership of the shares of common stock offered hereby. The second column lists the number of shares of common stock beneficially owned by the selling stockholders as of February&nbsp;29, 2024
unless otherwise indicated in the footnotes to the table. The selling stockholders may have sold or transferred some or all of the common stock indicated below and may in the future sell or transfer some or all of the common stock indicated below in
transactions exempt from the registration requirements of the Securities Act rather than under this prospectus. The third column lists the shares of common stock being offered by this prospectus by the selling stockholders. The fourth column assumes
the sale of all of the shares of common stock offered by the selling stockholders pursuant to this prospectus. The selling stockholders may sell all, some or none of their shares of common stock in this offering. See &#147;<I>Plan of
Distribution</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as indicated by the footnotes below, we believe, based on the information furnished
to us, that the selling stockholders have sole voting and investment power with respect to all shares of common stock that they own, subject to applicable community property laws. Beneficial ownership for the purposes of the table below is
determined in accordance with the rules and regulations of the SEC. These rules generally provide that a person is the beneficial owner of securities if such person has or shares the power to vote or direct the voting thereof, or to dispose or
direct the disposition thereof or has the right to acquire such powers within 60 days. Percentage of beneficial ownership is based on 9,368,262 shares of common stock outstanding as of November&nbsp;7, 2024. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP><B>Name and Address of Selling Stockholders</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;Shares<BR>Beneficially<BR>Owned&nbsp;Before<BR>the&nbsp;Offering</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares&nbsp;that<BR>May Be<BR>Offered<BR>Hereby(11)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Beneficially&nbsp;Owned<BR>After the Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Select Portfolios: Biotechnology Portfolio(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Growth Company Commingled Pool(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual Fund Series Trust, on behalf of Eventide Healthcare&nbsp;&amp; Life Sciences
Fund(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">546,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">369,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Point72 Asset Management(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">542,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">265,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">276,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel CEMF Investments Ltd.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">265,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">265,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Cormorant(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">529,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">265,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus Public Equities, L.P.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">419,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qiming U.S. Healthcare Fund II, L.P.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">368,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">332,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Sixty Degree Capital(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MP Healthcare Venture Management, Inc.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ExodusPoint Partners Master Fund, L.P.(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These accounts are managed by direct or indirect subsidiaries of FMR LLC. The shares listed above are
beneficially owned, or may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the
Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B
shareholders have entered into a shareholders&#146; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting
common shares and the execution of the shareholders&#146; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of FMR LLC is 245
Summer Street, Boston, MA&nbsp;02210. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares listed under &#147;Number of Shares Beneficially Owned Before the Offering&#148; consists of 546,225
shares held by Mutual Fund Series Trust, on behalf of Eventide Healthcare&nbsp;&amp; Life Sciences Fund, or Eventide, as of March&nbsp;22, 2024. Eventide Asset Management, LLC is the investment advisor to Eventide.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Robin C. John is the Chief Executive Officer of Eventide Asset Management, LLC and Finny Kuruvilla, M.D., Ph.D. is a <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Investment Officer and
Managing Director of Eventide Asset Management, LLC. In their corporate capacity for Eventide Asset Management, LLC, Mr.&nbsp;John and Dr.&nbsp;Kuruvilla hold voting and/or dispositive power over the shares held by Eventide. Mr.&nbsp;John and
Dr.&nbsp;Kuruvilla disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address for Eventide, Mr.&nbsp;John and Dr.&nbsp;Kuruvilla is U.S. Bank Trust Services, Physical Processing, <FONT
STYLE="white-space:nowrap">MK-WI</FONT> S302, 1555 N RiverCenter Drive, Suite 302, Milwaukee, WI 53212. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares listed under &#147;Number of Shares Beneficially Owned Before the Offering&#148; consists of (i) 276,831
shares held by Point72 Biotech Private Investments, LLC, or Point72 Biotech, and (ii) 265,826 shares held by Point72 Associates, LLC, or Point72 Associates. Differentiated Ventures Investments, LLC, or Differentiated Ventures, is the managing member
of Point72 Biotech and may be deemed to share beneficial ownership of the shares held by Point72 Biotech. 72 Investment Holdings, LLC, or 72 Investment Holdings, is the sole member of Differentiated Ventures and may be deemed to share beneficial
ownership of the shares of which Differentiated Ventures may be deemed to share beneficial ownership. Steven A. Cohen, or Mr.&nbsp;Cohen, is the sole member of 72 Investment Holdings and may be deemed to share beneficial ownership of the shares of
which 72 Investment Holdings may be deemed to share beneficial ownership. Each of Differentiated Ventures, 72 Investment Holdings and Mr.&nbsp;Cohen disclaims beneficial ownership of the shares held by Point72 Biotech. Pursuant to an investment
management agreement, Point72 Asset Management, L.P., or Point72 Asset Management, maintains investment and voting power with respect to the shares held by Point72 Associates and therefore may be deemed to share beneficial ownership of such shares.
Point72 Capital Advisors, Inc., or Point72 Capital Advisors, is the general partner of Point72 Asset Management and may be deemed to share beneficial ownership of the shares of which Point72 Asset Management may be deemed to share beneficial
ownership. Mr.&nbsp;Cohen is the sole member of Point72 Capital Advisors and may be deemed to share beneficial ownership of the shares of which Point72 Capital Advisors may be deemed to share beneficial ownership. Each of Point72 Asset Management,
Point72 Capital Advisors and Mr.&nbsp;Cohen disclaims beneficial ownership of the shares held by Point72 Associates. The address for Point72 Biotech and Point72 Associates is c/o Point72, L.P., 72 Cummings Point Road, Stamford, CT 06902.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares listed under &#147;Number of Shares Beneficially Owned Before the Offering&#148; consists of 265,826
shares held by Citadel CEMF Investments Ltd. Citadel Advisors LLC is the portfolio manager of Citadel CEMF Investments Ltd. Citadel Advisors Holdings LP, or CAH, is the sole member of Citadel Advisors LLC. Citadel GP LLC, or CGP, is the general
partner of CAH. Kenneth Griffin owns a controlling interest in CGP. Mr.&nbsp;Griffin, as the owner of a controlling interest in CGP, may be deemed to have shared power to vote or direct the vote of, and/or shared power to dispose or to direct the
disposition over, the shares covered by this registration statement. This response is not and shall not be construed as an admission that Mr.&nbsp;Griffin or any of the Citadel related entities listed above is the beneficial owner of any securities
of the Company other than the securities actually owned by such person (if any). The address of Citadel CEMF Investments Ltd. is c/o Citadel Enterprise Americas, Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, FL 33131.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares listed under &#147;Number of Shares Beneficially Owned Before the Offering&#148; consists of (i) 312,052
shares held by Cormorant Global Healthcare Master Fund, LP, or Master Fund, and (ii) 217,118 shares held by Cormorant Private Healthcare Fund II, LP, or Fund II. Cormorant Global Healthcare GP, LLC, or Global GP, and Cormorant Private Healthcare GP
II, LLC, or Private GP II, serve as the general partner of Master Fund and Fund II, respectively. Cormorant Asset Management, LP serves as the investment manager to Master Fund and Fund II. Bihua Chen serves as the managing member of Global GP,
Private GP II and Cormorant Asset Management, LP. Each of Global GP, Private GP II, Cormorant Asset Management, LP and Ms.&nbsp;Chen disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. The principal
address for the Cormorant Asset Management LP entities is 200 Clarendon Street 52nd Floor, Boston, Massachusetts 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares listed under &#147;Number of Shares Beneficially Owned Before the Offering&#148; consist of 419,226
shares held by Invus Public Equities, L.P., or IPE. Invus Public Equities Advisors, LLC, or IPEA, controls IPE, as its general partner and accordingly, may be deemed to beneficially own the Shares held by IPE. Invus
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Global Management, LLC, or IGM, controls IPEA, as its managing member and accordingly, may be deemed to beneficially own the Shares that IPEA may be deemed to beneficially own. Siren, L.L.C., or
Siren, controls IGM, as its managing member and accordingly, may be deemed to beneficially own the Shares that IGM may be deemed to beneficially own. Mr.&nbsp;Raymond Debbane, as the managing member of Siren, controls Siren and accordingly, may be
deemed to beneficially own the Shares that Siren may be deemed to beneficially own. The address for IPE, IPEA, IGM, Siren and Mr.&nbsp;Raymond Debbane is 750&nbsp;Lexington Avenue, 30th Floor, New York, NY 10022. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares listed under &#147;Number of Shares Beneficially Owned Before the Offering&#148; consists of 368,085
shares held by Qiming U.S. Healthcare Fund II, L.P, or Qiming. Qiming U.S. Healthcare GP II, LLC, or Qiming GP, serves as the sole general partner of Qiming. As such, Qiming GP possesses power to direct the voting and disposition of the shares owned
by Qiming and may be deemed to have indirect beneficial ownership of the shares held by Qiming. Mark McDade and Gary Rieschel are the managing partners of Qiming GP. As such, each of Mark McDade and Gary Rieschel possesses power to direct the voting
and disposition of the shares owned by Qiming and may be deemed to have indirect beneficial ownership of these shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares listed under &#147;Number of Shares Beneficially Owned Before the Offering&#148; consists of (i) 26,941
shares held by Sixty Degree Capital Fund <FONT STYLE="white-space:nowrap">II-A,</FONT> L.P., or Sixty Degree Fund <FONT STYLE="white-space:nowrap">II-A,</FONT> and (ii) 4,620 shares held by Sixty Degree Capital Fund II, L.P., or Sixty Degree Fund
II. The general partner of Sixty Degree Fund <FONT STYLE="white-space:nowrap">II-A</FONT> and of Sixty Degree Fund II is Sixty Degree Capital Fund II GP Inc. The manager of Sixty Degree Fund <FONT STYLE="white-space:nowrap">II-A</FONT> and of Sixty
Degree Fund II is Sixty Degree Capital Inc. Each of Sixty Degree Capital Inc. and Sixty Degree Fund <FONT STYLE="white-space:nowrap">II-A</FONT> may be deemed to beneficially own the shares held by Sixty Degree Fund
<FONT STYLE="white-space:nowrap">II-A</FONT> and each of Sixty Degree Capital Inc. and Sixty Degree Fund II may be deemed to beneficially own the shares held by Sixty Degree Fund II. The address of the principal business office of Sixty Degree Fund <FONT
STYLE="white-space:nowrap">II-A,</FONT> Sixty Degree Fund II, Sixty Degree Capital Fund II GP Inc. and Sixty Degree Capital Inc. is 251&nbsp;Consumers Rd, #1100, Toronto, ON Canada M2J 4R3. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares listed under &#147;Number of Shares Beneficially Owned Before the Offering&#148; consist of 177,666
shares held by MP Healthcare Venture Management, Inc., or MP Healthcare, as of March&nbsp;22, 2024. Mitsubishi Tanabe Pharma America, Inc. is the sole shareholder of MP Healthcare. Mitsubishi Tanabe Pharma Corporation is the sole shareholder of
Mitsubishi Tanabe Pharma America, Inc. Mitsubishi Chemical Group Corporation is the sole shareholder of Mitsubishi Tanabe Pharma Corporation. As a result, Mitsubishi Tanabe Pharma America, Inc., Mitsubishi Tanabe Pharma Corporation and Mitsubishi
Chemical Group Corporation may be deemed to share beneficial ownership of the shares held by MP Healthcare. The principal business address of MP Healthcare is 245 Main Street, 2nd Floor, Cambridge, MA 02142 and the principal business address of
Mitsubishi Tanabe Pharma America, Inc., Mitsubishi Tanabe Pharma Corporation and Mitsubishi Chemical Group Corporation <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3-2-10,</FONT></FONT> Dosho-machi, <FONT
STYLE="white-space:nowrap">Chuo-ku,</FONT> Osaka, <FONT STYLE="white-space:nowrap">541-8505,</FONT> Japan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares listed under &#147;Number of Shares Beneficially Owned Before the Offering&#148; consists of 42,527
shares held by ExodusPoint Partners Master Fund, L.P, or Exodus. ExodusPoint Capital Management, LP acts as the investment manager to Exodus. Michael Gelband and Hyung Lee, the <FONT STYLE="white-space:nowrap">co-founders</FONT> and <FONT
STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officers of ExodusPoint Capital Management, LP, have voting and investment control of the shares held by Exodus. The business address of Exodus, Michael Gelband and Hyung Lee is 190 Elgin Avenue,
George Town, Grant Cayman, Cayman Islands <FONT STYLE="white-space:nowrap">KY1-9008.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No other shares of common stock, including, without limitation, shares of common stock acquired in the open
market are being offered under this prospectus. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom870524_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each selling stockholder of the securities and any of their pledgees, assignees, donees, transferees or other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> may, from time to time, sell, transfer or otherwise dispose of any or all of their securities covered hereby on the Nasdaq Global Select Market,
the Nasdaq Global Market, the Nasdaq Capital Market, or the New York Stock Exchange or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated
prices. A selling stockholder may use any one or more of the following methods when selling securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell
a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions through broker-dealers that agree with the selling stockholders to sell a specified number of
such securities at a stipulated price per security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if
available, rather than under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the selling stockholders may arrange for other brokers-dealers to
participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set
forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with
FINRA Rule 2121. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of the securities or interests therein, the selling stockholders may enter into hedging
transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The selling stockholders may also sell securities short and deliver these
securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other
financial institutions or create one or more derivative securities that require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial
institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). The selling stockholders also may transfer the securities in other circumstances, in which case the transferees, pledgees, donees or other
successors in interest will be the selling beneficial owners for purposes of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders and any
broker-dealers or agents that are involved in selling the securities may be deemed to be &#147;underwriters&#148; within the meaning of the Securities Act in connection with such sales (it being understood that the selling stockholders shall not be
deemed to be underwriters solely as a result of their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
participation in this offering). In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be
underwriting commissions or discounts under the Securities Act. Each selling stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to pay certain fees and expenses incurred by us incident to the registration of the securities. We have agreed to indemnify
the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
agreed to keep this prospectus effective until the earlier of the date that the securities (i)&nbsp;have been sold, pursuant to this prospectus or pursuant to Rule 144, or (ii)&nbsp;the date on which the securities may be resold by the selling
stockholders without registration and without regard to any volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations by reason of Rule 144, and without the requirement for us to be in
compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state
securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement
is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution
of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the
selling stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the selling stockholders or
any other person. We will make copies of this prospectus available to the selling stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance
with Rule 172 under the Securities Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds from sales of any shares of common stock by the selling
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that the selling stockholders will sell all or any portion of the shares of common stock offered
hereby. We are registering the resale of shares of our common stock to provide the selling stockholders with freely tradable securities, but the registration of such shares does not necessarily mean that any of such shares will be offered or sold by
the selling stockholders pursuant to this prospectus or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, this prospectus may be amended and/or
supplemented from time to time to describe a specific plan of distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom870524_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the common stock being offered by this prospectus has been passed upon for us by Goodwin Procter LLP, Boston,
Massachusetts.<B></B><B>&nbsp;</B> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom870524_9"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Korro Bio, Inc. appearing in Korro Bio, Inc.&#146;s Annual Report (Form <FONT
STYLE="white-space:nowrap">10-K)</FONT> for the year ended December&nbsp;31, 2023 have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and
incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom870524_10"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains
reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is <I>www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our website address is <I>www.korrobio.com</I>. The information on our website, however, is not, and should not be deemed to be, a part of
this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not
contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Other documents establishing the terms of the offered securities are or may be filed as exhibits to
the registration statement or documents incorporated by reference in the registration statement. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by
reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement through the SEC&#146;s website, as provided above.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom870524_11"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important
information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with
the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by
reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below and any future filings
we make with the SEC under Sections 13(a), 13(c), 14 or 15(d)&nbsp;of the Securities Exchange Act of 1934, as amended, or the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) until the
offering of the securities under the registration statement is terminated or completed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1703647/000095017024036396/krro-20231231.htm"><FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT></A>&nbsp;for the fiscal year ended December&nbsp;31, 2023, filed
with the SEC on March&nbsp;26, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarters ended
March&nbsp;31, 2024, June&nbsp;30, 2024 and September&nbsp;30, 2024, as filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001703647/000095017024059493/krro-20240331.htm">May&nbsp;14,
2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001703647/000095017024096189/krro-20240630.htm">August&nbsp;
13, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001703647/000095017024125362/krro-20240930.htm">November&nbsp;12, 2024</A>, respectively; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> as filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001703647/000119312524004911/d466614d8k.htm">January&nbsp;9,
 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001703647/000119312524100069/d803577d8k.htm">April&nbsp;
18, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001703647/000119312524105037/d814636d8k.htm">April&nbsp;
22, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001703647/000095017024059498/krro-20240513.htm">May&nbsp;
14, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001703647/000119312524159933/d844802d8k.htm">June&nbsp;
12, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001703647/000119312524165684/d847854d8k.htm">June&nbsp;
21, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001703647/000095017024101395/krro-20240826.htm">August&nbsp;
28, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001703647/000095017024106611/krro-20240913.htm">September&nbsp;
16, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001703647/000095017024120282/krro-20241104.htm">November&nbsp;
4, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001703647/000095017024129488/krro-20241121.htm">November&nbsp;21, 2024</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our Registration Statement on&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1703647/000119312519251258/d799941d8a12b.htm"><FONT STYLE="white-space:nowrap">Form&nbsp;8-A</FONT></A> <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;001-39062),</FONT> filed&nbsp;with the SEC on
September&nbsp;23, 2019, including any amendments or reports filed for the purpose of updating such description, including&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1703647/000095017024036396/krro-ex4_1.htm">Exhibit 4.1</A>&nbsp;to our
Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the fiscal year ended December&nbsp;31, 2023. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be
modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the
statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written
or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents. Any such request may be made by writing or calling us at the following address or phone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Korro Bio, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 First Street,
2nd floor, Suite 250 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cambridge, Massachusetts 02141 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn:&nbsp;Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(617) <FONT STYLE="white-space:nowrap">468-1999</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g870524g04x04.jpg" ALT="LOGO" STYLE="width:1.51684in;height:0.288028in;">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Up to 1,504,537 Shares of Common Stock </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;9, 2024 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g870524g04x04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g870524g04x04.jpg
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\
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M_5W\)G?><F'G'GW%NNN**EK6HE2B>))/$Q<,=\LCD-6YM=+GJ:UHI08I,N>
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M=M-NI:IB7E/+2@$*=)P<*.=X!&<>O.Z/ CL+DIE$BW.J8=$HXM32'BD["E@
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EFDSK,PAQ=70H#.X,'J_O0000<-#@2XC]V*R?%=7)VY_9?@__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
